Skip to main content
. Author manuscript; available in PMC: 2023 Nov 1.
Published in final edited form as: Psychopharmacology (Berl). 2022 Sep 13;239(11):3539–3550. doi: 10.1007/s00213-022-06226-1

Figure 1. RNA sequencing reveals discrete transcriptomics for altered biological processes based on nociceptive induction and treatments.

Figure 1.

(a) Experimental timeline for RNA sequencing of the mPFC under various treatment conditions. (b) mRNA transcript profile comparing saline-treated rats that did not receive CFA to rats that received CFA. (c) mRNA transcript profile comparing CFA-treated rats that received either saline or oxycodone. (d) mRNA transcript profile comparing saline versus oxycodone treatments in rats that did not receive CFA. (e) mRNA transcript profile comparing oxycodone-treated rats that did not receive CFA to rats that received CFA. (f) Egr3 transcript changes expressed as fragments per kilobase of exon per million mapped fragments (FKPM) between CFA and saline rats that received either oxycodone or saline. (g) mRNA expression of Egr3 expressed in fold change between CFA and saline rats that received either oxycodone or saline. All data are presented as means ± SEMs with statistical significance (*) at P < 0.05. * represents significant differences between oxycodone groups of saline and CFA with their respective controls (saline + saline and saline + CFA)